Early drug trial halted for lung transplant complication
NCT ID NCT03978637
Summary
This early-stage study tested a drug called itacitinib for people who developed a serious lung complication called BOS after a double lung transplant. The main goals were to check the drug's safety and see if it could help improve or stabilize patients' breathing. The trial involved 23 participants but was stopped early (terminated).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women'S Faulkner Hospitals Inc
Boston, Massachusetts, 02115, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Duke University Health System
Durham, North Carolina, 27710, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Temple University Department of Thoracic Medicine and Surgery
Philadelphia, Pennsylvania, 19140, United States
-
UPMC
Pittsburgh, Pennsylvania, 15213, United States
-
Universitaire Ziekenhuis Leuven - Gasthuisberg
Leuven, 03000, Belgium
-
University Health Network Toronto General Hospital
Toronto, Ontario, M5G 2N2, Canada
-
University of California, Los Angeles - David Geffen School of Medicine
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.